Sakai Hiroshi, Shinjyo Sayo, Nakamura Yoshimi, Nakamura Yuko, Ishikawa Shusaku, Sawaguchi Shoichi
Department of Ophthalmology, University of the Ryukyus Faculty of Medicine, Okinawa, Japan.
J Ocul Pharmacol Ther. 2005 Dec;21(6):483-9. doi: 10.1089/jop.2005.21.483.
To compare the efficacy, adverse effects, and patient compliance of latanoprost monotherapy with unfixed combination therapy with 0.5% timolol maleate and 1% dorzolamide in the treatment of chronic primary angle-closure glaucoma (CACG), 36 Japanese patients with CACG following laser iridotomy (LPI) were treated for 12 weeks with instillation of latanoprost alone or with unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride. After 12 weeks of treatment, latanoprost reduced intraocular pressure (IOP) from 22.2 +/- 2.0 mmHg to 14.8 +/- 1.9 mmHg (33% reduction); timolol maleate and dorzolamide hydrochloride also reduced IOP from 22.5 +/- 2.2 mmHg to 17.1 +/- 2.7 mmHg (24% reduction). Latanoprost monotherapy significantly lowered IOP compared with unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride. Furthermore, a systemic adverse effect of bradycardia was not observed in the latanoprost monotherapy group. Concerning compliance, no significant difference was observed between the two groups. Thus, latanoprost monotherapy is more effective than unfixed combination therapy with 0.5% timolol maleate and 1% dorzolamide in the treatment of CACG following relief of pupillary block in Japanese patients.
为比较拉坦前列素单药治疗与0.5%马来酸噻吗洛尔和1%多佐胺未固定联合治疗对慢性原发性闭角型青光眼（CACG）的疗效、不良反应及患者依从性，36例日本激光虹膜切开术（LPI）后患有CACG的患者接受了为期12周的治疗，单独滴注拉坦前列素或采用0.5%马来酸噻吗洛尔和1%盐酸多佐胺的未固定联合治疗。治疗12周后，拉坦前列素使眼压（IOP）从22.2±2.0 mmHg降至14.8±1.9 mmHg（降低33%）；马来酸噻吗洛尔和盐酸多佐胺也使眼压从22.5±2.2 mmHg降至17.1±2.7 mmHg（降低24%）。与0.5%马来酸噻吗洛尔和1%盐酸多佐胺的未固定联合治疗相比，拉坦前列素单药治疗显著降低了眼压。此外，拉坦前列素单药治疗组未观察到心动过缓的全身性不良反应。关于依从性，两组之间未观察到显著差异。因此，在日本患者瞳孔阻滞缓解后的CACG治疗中，拉坦前列素单药治疗比0.5%马来酸噻吗洛尔和1%多佐胺的未固定联合治疗更有效。
